Avalo Therapeutics Inc (AVTX) stock news · rev $59.0K
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
This AVTX news page leads with what Avalo Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for AVTX yet. We will not pad this page with generic market recap.
Latest reported AVTX revenue for 2025-12-31 was $59.0K. Net income was -$78.3M. Revenue was down 86.6% from 2024-12-31 to 2025-12-31. AVTX currently screens at market cap $51.5M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the AVTX stock page; for the tape open the quote page.
AVTX stock news FAQ
What are AVTX's latest revenue and net income?
Latest cached Avalo Therapeutics Inc (AVTX) revenue for Dec 31, 2025 was $59.0K. Net income was -$78.3M. Statements: https://lician.com/financials/avtx
How did AVTX revenue change from the prior cached period?
Cached Avalo Therapeutics Inc (AVTX) revenue was down 86.6% from $441.0K (Dec 31, 2024) to $59.0K (Dec 31, 2025). Statements: https://lician.com/financials/avtx
What is AVTX's market cap?
Avalo Therapeutics Inc (AVTX) market cap is $51.5M on the latest cached fundamentals snapshot.
What kind of company is AVTX?
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
Where is AVTX stock news listed?
Cached stock news for Avalo Therapeutics Inc (AVTX) is listed at https://lician.com/news/avtx. Filings: https://lician.com/sec/avtx
Not investment advice.